Group 1 - The research team from Wuhan Institute of Virology, Shanghai Institute of Materia Medica, and Wangshan Wangshui Biopharmaceutical Co., Ltd. published significant findings confirming the antiviral activity of oral nucleoside drug VV116 against Nipah virus, providing new hope for the prevention and treatment of this high-mortality emerging infectious disease [1][8] - VV116 has been validated for its therapeutic potential against Nipah virus, serving as a preventive medication for high-risk groups such as healthcare workers and laboratory personnel, and offering a ready drug option for current and future Nipah virus outbreaks [1][8] Group 2 - Wangshan Wangshui Biopharmaceutical Co., Ltd. is a wholly-owned subsidiary of Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd., which is listed on the Hong Kong Stock Exchange [3][10] - The stock price of Wangshan Wangshui surged over 14% in early trading, reaching a historical high of 112.7 HKD per share, with a trading volume of 2,615 million HKD [3][10] - The company focuses on innovative drug development in the fields of viral infections, neuropsychiatry, and reproductive health, with a comprehensive system covering drug discovery to commercialization [10][11] - Currently, Wangshan Wangshui has two innovative drugs in the commercialization stage, five candidates in clinical trials, and three candidates in preclinical research [10][11] - VV116 is a broad-spectrum antiviral oral nucleoside RNA-dependent RNA polymerase inhibitor, already approved for COVID-19 indications in China and Uzbekistan [10][11] Group 3 - In December 2025, Wangshan Wangshui announced a licensing and collaboration agreement with Ascletis Pharma, granting exclusive rights for the development, manufacturing, and commercialization of VV116 for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) infections in Greater China [6][13]
武汉病毒研究所：发现对尼帕病毒有效药物